J07AN01 - Tuberculosis, Live Attenuated |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the tuberculosis, live attenuated vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Live attenuated Mycobacterium bovis BCG (Bacillus Calmette-Guérin).
Therapeutic characteristics
The tuberculosis, live attenuated vaccine (BCG vaccine) is indicated for active immunization against against tuberculosis in individuals from the age of 6 weeks to 35 years.
It is administered as a single intradermal injection.
Metabolism and pharmakokinetics
The BCG vaccine is not metabolized by the cytochrome P450 system.
References
- Government bodies
- Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015). #1857
- Summary of Product Characteristics
- Norwegian medicines agency. Summary of Product Characteristics (SPC). BCG-vaksine SSI. #1869
Similar drugs
© NAPOS 2024